[ad_1]
Summit Therapeutics (NASDAQ:SMMT) is likely one of the 17 biotechnology shares with greater than 50% upside.
As of the shut of play on February 12, consensus sentiment round Summit Therapeutics (NASDAQ:SMMT) was reasonably bullish. The inventory had obtained protection from 6 analysts, 4 of whom had assigned Purchase rankings and a couple of gave Maintain calls. With no Promote score, the inventory carries a projected median 1-year value goal of $57.98, implying a robust upside of greater than 296%.
Pressmaster/Shutterstock.com
Again on January 29, Summit Therapeutics (NASDAQ:SMMT) confirmed that the U.S. FDA had accepted its software for ivonescimab, a lung most cancers therapy for use together with chemotherapy in sufferers who’ve progressed after focused remedy. The appliance is backed by outcomes from the worldwide part III HARMONi trial knowledge, with November 14, 2026, being the choice date.
The appliance goals to fill a market hole by catering to 14,000 eligible U.S. sufferers yearly, together with the prevailing business publicity in China via the corporate’s partnership with Akeso. This positions Summit Therapeutics (NASDAQ:SMMT) to probably enter the U.S. oncology market if authorized.
Summit Therapeutics (NASDAQ:SMMT) is a clinical-stage biopharmaceutical firm that develops and commercializes medical oncology therapies. It’s targeted on creating ivonescimab, a bispecific antibody that mixes blockade of PD-1 and anti-angiogenesis in a single molecule. It’s also operating Part III scientific trials for the therapy of non-small lung most cancers.
Whereas we acknowledge the potential of SMMT as an funding, we consider sure AI shares supply better upside potential and carry much less draw back danger. In the event you’re on the lookout for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the finest short-term AI inventory.
READ NEXT: 15 Most Promising Mid-Cap Healthcare Shares Underneath $50 and 11 Most Promising Small-Cap Industrial Shares Underneath $50.
Disclosure: None. This text is initially revealed at Insider Monkey.
[ad_2]
